Clinical trials: Prostatic Hypertrophy
- Condition Prostatic Hypertrophy
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Prostatic Hyperplasia
Observational Study of ALNA® (Tamsulosin) in Patients With Benign Prostatic Hyperplasia (BPH)
The objectives of this post marketing surveillance study were to document the comorbidity and comedication during prescription of ALNA® (Tamsulosin) for patients with BPH (Benign Prostatic Hyperplasia).
- Trial name
- NCT02245503
- Testing
- Tamsulosin
- Volunteers
- 7,391 people
- Sponsor
- Boehringer Ingelheim
Prostatic Hyperplasia
Observational AVODART (Dutasteride) Study In Benign Prostatic Hyperplasia Subjects - OASIS
This study was designed to assess the effectiveness of dutasteride in the actual clinical practice of prostate assessment clinics in the UK in accordance with best practice over a 12-month period.
- Trial name
- NCT00316732
- Testing
- IPSS Questionnaire, EQ-5D Questionnaire
- Where
- 27 sites in United Kingdom
- Volunteers
- 173 people
- Sponsor
- GlaxoSmithKline
Prostatic Hyperplasia
Prescription Event Monitoring in Patients With Benign Prostatic Hyperplasia (BPH)
Study to evaluate the safety profile of Secotex® in the improvement of the symptoms of Benign Prostatic Hyperplasia in real clinical practice
- Trial name
- NCT02244346
- Testing
- Secotex®
- Volunteers
- 811 people
- Sponsor
- Boehringer Ingelheim
Prostatic Hyperplasia
Observational Study in Patients Suffering From Benign Prostatic Hyperplasia Treated With Alpha-adrenergic Blockade
The primary objective of this observational study was the assessment of prognosis factors for having recourse to prostatic surgery in patients with BPH who were administered class-1 alpha blockers.
- Trial name
- NCT02244307
- Testing
- alpha-adrenergic blocker
- Volunteers
- 4,561 people
- Sponsor
- Boehringer Ingelheim
Benign Prostatic Hyperplasia
Dose Escalation Study With QLT0074 for Benign Prostatic Hyperplasia
The primary objective of this study is to assess the safety and tolerance of transurethral photodynamic therapy (PDT) with QLT0074. Secondary objectives are: 1.
- Trial name
- NCT00077012
- Testing
- QLT0074, Photodynamic therapy
- Where
- 7 sites in United States, Canada
- Sponsor
- QLT Inc.
Benign Prostatic Hyperplasia, Localized Prostate Cancer
PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs
The goal of this clinical trial is to assess the performance and safety of the AQUABEAM Robotic System for the resection and removal of prostate tissue in patients experiencing lower urinary tract symptoms (LUTS) and are…
- Trial name
- NCT06051942
- Testing
- Robotic Waterjet Treatment
- Where
- 6 sites in United States, Hong Kong and 2 more
- Volunteers
- 125 people
- Sponsor
- PROCEPT BioRobotics
Benign Prostatic Hyperplasia (BPH)
A Multi-center, International Prospective Follow up Study
The study objective is to assess the safety and efficacy of iTind three to five years following treatment.
- Trial name
- NCT04579913
- Testing
- Review of medical history, administration of questionnaires, uroflowmetry and PVR as measured by ultrasound
- Where
- 5 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- Medi-Tate Ltd.
Urinary Calculi, Benign Prostatic Hyperplasia
Flexiva Pulse Registry
To obtain post-market safety and efficacy data for FlexivaTM Pulse High Power Single-Use Laser Fibers during lithotripsy and soft tissue procedure of holmium laser enucleation of the prostate (HoLEP).
- Trial name
- NCT05027971
- Testing
- Flexiva Pulse High Power Single-Use Laser Fibers
- Where
- 4 sites in United States
- Volunteers
- 201 people
- Sponsor
- Boston Scientific Corporation
Bladder Cancer
Loop Resectoscope in Treating Patients With Bladder Cancer or Benign Prostatic Hyperplasia Who Are Undergoing Transurethral Resection
RATIONALE: Transurethral resection is a less invasive type of surgery for bladder cancer or benign prostatic hyperplasia. Transurethral resection using a loop resectoscope may have fewer side effects and improve recovery.
- Trial name
- NCT00303654
- Testing
- biopsy, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Roei Medical Technologies Ltd.
Prostatic Hyperplasia
Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)
The objective of the observational study were to investigate the switch from phytotherapy to ALNA® after at least 4 weeks of phytotherapy and still presented with a symptom sum score of ≥ 8 points (International Prostate Symptom…
- Trial name
- NCT02244320
- Testing
- Tamsulosin
- Volunteers
- 4,150 people
- Sponsor
- Boehringer Ingelheim
Benign Prostate Hypertrophy(BPH), Renal Calculi
Stone and Laser Therapies Post-Market Study (SALT)
The objective of the SALT Study is to obtain post-market safety and device performance data for Boston Scientific's Stone and BPH study devices used during a diagnostic and/or therapeutic urinary tract procedure (e.g.…
- Conditions
- Benign Prostate Hypertrophy(BPH), Renal Calculi, Ureteral Stones, Kidney Stones, Calculi, Urinary
- Trial name
- SALT (NCT06982235)
- Testing
- Ureteroscope system, Laser system
- Where
- 5 sites in United States
- Volunteers
- 238 people
- Sponsor
- Boston Scientific Corporation
Benign Prostatic Hyperplasia
GreenLight XPS Laser System Retrospective Chart Review
The purpose of this study is to gain information on the safety, efficacy, and quality of life in subjects who have had the GreenLight XPS procedure.
- Trial name
- NCT02139969
- Testing
- GreenLight XPS Laser System
- Where
- 6 sites in United States, Canada
- Volunteers
- 956 people
- Sponsor
- Boston Scientific Corporation
Prostatic Hyperplasia
ALF-ONE : ALFuzosin ONcE Daily
The aim of the study is to collect, under daily practice conditions, clinical data on the safety profile and the efficacy of a new formulation of alfuzosin administered once daily in patients with lower urinary tract symptoms…
- Trial name
- NCT00280605
- Testing
- Alfuzosin
- Volunteers
- 200 people
- Sponsor
- Sanofi
Benign Prostatic Hyperplasia
OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH
APEX is a prospective multi-site registry of real-world experience with the Optilume™ BPH Catheter System for treatment of men experiencing symptomatic BPH.
- Trial name
- APEX (NCT06560476)
- Testing
- Data collection
- Where
- 8 sites in United States
- Volunteers
- 500 people
- Sponsor
- Urotronic Inc.
Prostatic Hyperplasia
Drug Use Investigation for AVOLVE(BPH)
The study is designed to investigate the safety and efficacy of dutasteride capsules 0.5 mg collected from the required number of Japanese subjects with benign prostatic hyperplasia (BPH) in order to identify concerns or…
- Trial name
- NCT01376284
- Testing
- Dutasteride
- Volunteers
- 1,000 people
- Sponsor
- GlaxoSmithKline
Prostatic Hyperplasia
The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)
Study to assess efficacy, tolerability and safety parameters of a three month ALNA®OCAS® -treatment with special respect to nocturia
- Trial name
- NCT02245542
- Testing
- ALNA®OCAS®
- Volunteers
- 5,775 people
- Sponsor
- Boehringer Ingelheim
Benign Prostatic Hyperplasia, Prostatic Hyperplasia
AVODART(Dutasteride) Post-marketing Surveillance(PMS)
An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and/or efficacy of AVODART administered in Korean BPH patients according to the prescribing information
- Trial name
- AVO PMS (NCT01299571)
- Testing
- Dutasteride
- Where
- South Korea
- Volunteers
- 3,977 people
- Sponsor
- GlaxoSmithKline
Prostatic Hyperplasia
Safety Profile of Secotex ® in Patients With Benign Prostatic Hyperplasia
The Objective of this study is to conduct a Prescription Event Monitoring (PEM) involving patients treated with Secotex® (Tamsulosin) in "real life" settings.
- Trial name
- NCT02245529
- Testing
- Tamsulosin
- Volunteers
- 982 people
- Sponsor
- Boehringer Ingelheim
Prostate Cancer, Benign Prostatic Hyperplasia
Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma
Emerging from a differential proteomic study of sample pairs of prostate cancer and benign tissue, annexin A3 (ANXA3) was chosen as a potential novel biomarker for the early and non-invasive diagnosis of prostate cancer.
- Conditions
- Prostate Cancer, Benign Prostatic Hyperplasia, Prostatic Intraepithelial Neoplasia
- Trial name
- NCT00400894
- Volunteers
- 750 people
- Sponsor
- ProteoSys AG
Prostatic Hyperplasia
Study to Evaluate the Effect of ALNA® (Tamsulosin) on the Primary Symptoms of Benign Prostatic Hyperplasia
The aims of this observational study are to identify the primary BPH symptoms responsible for the patients to consult a urologic practice, resulting in the prescription of ALNA®, to assess the clincial efficacy on an improved…
- Trial name
- NCT02244268
- Testing
- ALNA®
- Volunteers
- 3,629 people
- Sponsor
- Boehringer Ingelheim